ADCT

ADC Therapeutics SA - 10-Q Summary (Q3 2025)

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2025. ADC Therapeutics SA is a commercial-stage biopharmaceutical company focused on antibody drug conjugates (ADCs). Its primary revenue driver is ZYNLONTA (loncastuximab tesirine-lpyl), approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company is also advancing a next-generation PSMA-targeting ADC. In June 2025, the Board approved a strategic restructuring plan to focus resources on ZYNLONTA expansion and the PSMA program, resulting in a ~30% global workforce reduction and the closure of the UK facility.

Key Financial Metrics

Note: Margins are not applicable as the company is in a net loss position. Gross profit for Q3 2025 was $15.2 million (93% margin) before operating expenses.

Material Changes vs. Prior Period

• Revenue: Q3 2025 product revenue decreased 12.6% to $15.8 million due to lower sales volume, partially offset by higher pricing and favorable gross-to-net adjustments. However, total revenue for the nine months ended September 30, 2025, increased 8.1% to $58.3 million, driven by a $5.0 million license milestone from Sobi upon Health Canada approval of ZYNLONTA.
• Operating Expenses: Total operating expenses decreased 12.3% in Q3 2025 compared to Q3 2024. R&D expenses dropped 17.5% due to the discontinuation of early-stage solid tumor programs and reduced spending on the ADCT-601 program. G&A expenses fell 16.8% due to lower professional fees and employee costs.
• Restructuring Costs: The company incurred $13.5 million in restructuring, impairment, and related costs for the nine months ended September 30, 2025, compared to zero in the prior year. This includes $6.2 million in severance and $6.4 million in asset impairments related to the UK facility closure.
• Financing: In June 2025, the company completed a private placement raising $93.1 million in net proceeds. In October 2025 (subsequent event), it raised an additional $57.6 million net.

Guidance, Outlook, and Risks

• Clinical Outlook: Topline data for the LOTIS-5 Phase 3 trial (ZYNLONTA + rituximab in 2L+ DLBCL) is expected in the first half of 2026. The LOTIS-7 trial (ZYNLONTA + glofitamab) showed an 86.7% complete response rate in early data; expanded enrollment is ongoing.
• Liquidity: Management believes current cash resources ($234.7 million as of Sept 30, plus $57.6 million from the October placement) are sufficient to fund operations for at least the next 12 months.
• Key Risks:
  • Regulatory & Pricing: Potential impact of U.S. "Most Favored Nation" (MFN) drug pricing policies and international trade tariffs on manufacturing costs.
  • Debt Obligations: Significant interest expense ($13.4 million in Q3) driven by the deferred royalty obligation with HCR and the senior secured term loan.
  • Restructuring Execution: Uncertainty regarding final costs associated with the UK facility closure and lease termination.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $292 million+ cash position (including subsequent financing) against the burn rate of ~$110 million per nine months in operating cash flow.
• Debt Service: Review the terms of the $115 million senior secured term loan and the $340 million deferred royalty obligation, specifically the accretion impact on net loss.
• Restructuring Costs: Confirm the finalization of the $13.5 million restructuring charge and any potential additional liabilities from the UK lease termination.
• Clinical Catalysts: Monitor the timeline for LOTIS-5 topline data (H1 2026) and the regulatory pathway for the 2L+ DLBCL indication.
• Revenue Mix: Assess the sustainability of product revenue growth given the 12.6% Q3 decline and reliance on the one-time $5M license milestone for YTD growth.